Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)
April 27, 2022 10:39 AM EDT
R&D
Coronavirus

Covid-19 roundup: Pfiz­er-BioN­Tech ask for kid boost­er EUA; No­var­tis, Mol­e­c­u­lar Part­ners may need an­oth­er tri­al for pan­dem­ic ther­a­py

Kyle LaHucik

Senior Reporter

Tyler Patchen

News Reporter

As both the de­bate and pres­sure re­main around giv­ing the youngest chil­dren a first dose of the Covid-19 vac­cine, Pfiz­er and BioN­Tech are mov­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times